Publicações

Medi5752 or Pembrolizumab (P) plus Carboplatin/Pemetrexed (Cp) in Treatment-Naive (1L) Non-Small Cell Lung Cancer (Nsclc): A Phase Ib/Ii Trial

AuthID
P-00X-M1A

Author(s)

Ahn, MJ

Kim, SW

Costa, EC

Rodriguez, LM

Oliveira, J

Molla, MAI

Majem, M

Costa, L

Su, WC

Lee, KH

Yang, JCH

Spigel, DR

Cho, EK

D'Arcangelo, M

Campelo, MRG

Delmonte, A

Mitchell, P

Achour, I

Subramaniam, D

Felip, E

Document Type

Abstract

Year published

2022

Published

in ANNALS OF ONCOLOGY, ISSN: 0923-7534

Volume: 33, Issue: 7, Pages: S1423-S1423 (1)

Conference

Annual Meeting of the European-Society-For-Medical-Oncology (Esmo), Date: SEP 09-13, 2022, Location: ELECTR NETWORK, Sponsors: European Soc Med Oncol

Indexing

Wos^®

Google Scholar^®

Metadata
Sources

Publication Identifiers

DOI: 10.1016/j.annonc.2022.08.058

Wos: WOS:000866211602468

Source Identifiers

ISSN: 0923-7534

Export Publication Metadata

Lista Marked

Adicionar à lista Marked

Info

At this moment we don't have any links to full text documens.

Medi5752 or Pembrolizumab (P) plus Carboplatin/Pemetrexed (Cp) in Treatment-Naive (1L) Non-Small Cell Lung Cancer (Nsclc): A Phase Ib/Ii Trial

Useful Links

Get Help

Autenticação Federada (Click on the image)

Medi5752 or Pembrolizumab (P) plus Carboplatin/Pemetrexed (Cp) in Treatment-Naive (1L) Non-Small Cell Lung Cancer (Nsclc): A Phase Ib/Ii Trial

Useful Links

Get Help